CFTR and cystic fibrosis: According to AbeonaTherapeutics [63], preclinical trials ofABO401, a new-generation capsid AAV204 developed by the company and carrying afunctional copy of the human mini-CFTR gene, show that theproduct effectively restores the main phenotypic attribute of CF, i.e.,chlorine channel functioning, in in vitro and in vivomodels.